EDTA
产品说明书
 |
同义名 : | Ethylenediaminetetraacetic acid |
| CAS号 : | 60-00-4 | |
| 货号 : | A287527 | |
| 分子式 : | C10H16N2O8 | |
| 纯度 : | 98% | |
| 分子量 : | 292.243 | |
| MDL号 : | MFCD00003541 | |
| 存储条件： |
Pure form Sealed in dry,Room Temperature In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
0.1 M NaOH: 6 mg/mL(20.53 mM)，配合低频超声，水浴加热至45℃，并调节pH至7 |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Ethylenediaminetetraacetic acid (EDTA) is a chelating agent commonly used in protein purification, both to eliminate contaminating divalent cations and to inhibit protease activity[3]. As a commonly used chelator, ethylenediaminetetraacetic acid (EDTA) enters soil environment inevitably and has the potential to cause negative effects on soil organisms. The toxicity of EDTA increased with the increase in concentration and exposure duration. The activities of antioxidant enzymes increased at low concentration and decreased at high concentration, which indicates that oxidative stress was induced by EDTA addition[4]. Ethylenediaminetetra-acetic acid (EDTA) is widely used as anticoagulant in laboratory medicine. EDTA-dependent pseudothrombocytopenia is a rare phenomenon (i.e., around 0.1% in the general population), which is mostly due to the presence of EDTA-dependent antiplatelet antibodies that react optimally between 0°C and 4°C, recognize the cytoadhesive receptors gpIIb-IIIa, stimulate the expression of activation antigens, trigger activation of tyrosine kinase, platelet agglutination and clumping in vitro, which finally lead to a spuriously decreased platelet count[5]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT03602807 | Transplant Dysfunction | Not Applicable | Recruiting | January 2020 | Denmark ... 展开 >> Odense University Hospital Recruiting Odense, Region Of Southern Denmark, Denmark, 5000 Contact: Ronja N Lundrup, BSc.med +45 40 76 40 05 rolun13@student.sdu.dk 收起 << |
| NCT02844686 | Coronary Artery Disease | Not Applicable | Unknown | August 2018 | - |
| NCT02901717 | Catheter-related Infections | Phase 3 | Recruiting | September 2019 | United States, Colorado ... 展开 >> University of Colorado Denver Recruiting Aurora, Colorado, United States, 80045 United States, District of Columbia Georgetown University Hospital Recruiting Washington, District of Columbia, United States, 20007 United States, Illinois University of Chicago Recruiting Chicago, Illinois, United States, 60637 United States, Kansas University of Kansas Cancer Center Recruiting Kansas City, Kansas, United States, 66160 United States, Massachusetts St. Vincent Hospital Recruiting Worcester, Massachusetts, United States, 01608 United States, Michigan Harper University Hospital Recruiting Detroit, Michigan, United States, 48201 Henry Ford Health Systems Recruiting Detroit, Michigan, United States, 48202 United States, Ohio University of Cincinnati Recruiting Cincinnati, Ohio, United States, 45219 United States, Oklahoma Oklahoma University Health Sciences Center Recruiting Oklahoma City, Oklahoma, United States, 73104 United States, Tennessee Methodist University Hospital Recruiting Memphis, Tennessee, United States, 38104 United States, Texas University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Puerto Rico VA Caribbean Healthcare System Recruiting San Juan, Puerto Rico, 00921 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
3.42mL 0.68mL 0.34mL |
17.11mL 3.42mL 1.71mL |
34.22mL 6.84mL 3.42mL |
| 参考文献 |
|---|